- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | EXTRAWELL PHAR (00858): PROFIT WARNING | - | HKEx | ||
| 16.06. | EXTRAWELL PHAR (00858): DATE OF BOARD MEETING | 2 | HKEx | ||
| 29.05. | EXTRAWELL PHAR (00858): (1) FURTHER EXTENSION OF LONG STOP DATE IN RESPECT OF PROPOSED FOURTH AMENDMENTS TO THE TERMS AND CONDITIONS OF THE BONDS (2) ... | - | HKEx | ||
| 14.04. | EXTRAWELL PHAR (00858): NEXT DAY DISCLOSURE RETURN | 3 | HKEx | ||
| 27.03. | EXTRAWELL PHAR (00858): MEMORANDUM OF UNDERSTANDING IN RELATION TO THE POSSIBLE SALE OF THE CONVERTIBLE BONDS | - | HKEx | ||
| 17.03. | EXTRAWELL PHAR (00858): COMPLETION OF DISCLOSEABLE TRANSACTION AND CONNECTED TRANSACTION AT SUBSIDIARY LEVEL IN RELATION TO A SHARE BUY-BACK TRANSACTION ... | - | HKEx | ||
| 27.02. | EXTRAWELL PHAR (00858): (1) EXTENSION OF LONG STOP DATE IN RESPECT OF PROPOSED FOURTH AMENDMENTS TO THE TERMS AND CONDITIONS OF THE BONDS (2) DELAY IN ... | - | HKEx | ||
| 20.01. | EXTRAWELL PHAR (00858): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | 2 | HKEx | ||
| EXTRAWELL PHARMACEUTICAL Aktie jetzt für 0€ handeln | |||||
| 20.01. | EXTRAWELL PHAR (00858): CHANGE OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND CHANGES IN COMPOSITION OF BOARD COMMITTEES | 1 | HKEx | ||
| 31.12.25 | EXTRAWELL PHAR (00858): CHANGE OF BUILDING NAME OF HEAD OFFICE AND PRINCIPAL PLACE OF BUSINESS IN HONG KONG | 2 | HKEx |
10 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| IONIS PHARMACEUTICALS | 71,40 | +0,11 % | Ionis grants Recordati rights to zilganersen for Alexander disease | ||
| CSPC PHARMA | 0,817 | +9,68 % | Dividendenbekanntmachungen (24.06.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) AH REALTY TRUST INC US04208T1088 0,14 USD 0,1229 EUR AMBEV SA ADR US02319V1035 0,0091 USD 0,008 EUR ARLANDASTAD GROUP AB SE0016276851 1... ► Artikel lesen | |
| SELLAS LIFE SCIENCES | 13,650 | +25,81 % | DesignRush: Brooke Sellas Joins DesignRush Podcast on Social Media's Revenue Risk | Miami, Florida--(Newsfile Corp. - June 23, 2026) - The latest episode of the DesignRush Podcast features Brooke Sellas, founder and CEO of B Squared Media. The episode explores why companies risk... ► Artikel lesen | |
| MADRIGAL PHARMACEUTICALS | 462,10 | +2,42 % | Piper Sandler reiterates Madrigal Pharmaceuticals stock rating | ||
| ACADIA PHARMACEUTICALS | 22,650 | +1,80 % | Acadia Pharmaceuticals Inc.: DAYBU (Trofinetide) vom CHMP für die Zulassung in der Europäischen Union empfohlen | - Die Entscheidung der Europäischen Kommission wird in den kommenden Monaten erwartet. - Im Falle einer Zulassung wird DAYBU die erste Behandlung von neurobehavioralen Symptomen des Rett-Syndroms... ► Artikel lesen | |
| CATALYST PHARMACEUTICALS | 27,500 | -0,72 % | CATALYST PHARMACEUTICALS, INC. - 8-K, Current Report | ||
| OPUS GENETICS | 3,460 | -1,70 % | Opus Genetics Aktie steigt nach Aufnahme in Russell Indizes | ||
| SAVARA | 5,360 | +3,51 % | Savara Inc.: Savara Announces the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) Has Accepted the MOLBREEVI* Marketing Authorisation Application (MAA) for Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) | -- MHRA's Acceptance Follows Acceptance/Validation of MOLBREEVI Biologics License Application (BLA) and MAA in Autoimmune PAP by the U.S. Food and Drug Administration (FDA) and the European Medicines... ► Artikel lesen | |
| ELITE PHARMACEUTICALS | - | - | Elite Pharmaceuticals, Inc.: Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2026 and Provides Conference Call Information | Northvale, New Jersey--(Newsfile Corp. - June 29, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products... ► Artikel lesen | |
| GALECTIN THERAPEUTICS | 4,480 | +2,75 % | Galectin Therapeutics Inc.: Galectin Therapeutics Announces Positive Type C Meeting with the FDA for Belapectin in Patients with MASH Cirrhosis and Portal Hypertension | Galectin has reached agreement with the FDA on the primary endpoint and regulatory path forward for the potential full approval of belapectinCompany intends to file the Phase 3 protocol in Q3 2026... ► Artikel lesen | |
| BIODEXA PHARMACEUTICALS | 2,880 | -1,37 % | Biodexa Pharmaceuticals PLC: Biodexa issues letter to Shareholders | May 14, 2026 Biodexa issues letter to Shareholders Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing innovative products focused on the treatment or... ► Artikel lesen | |
| NEURIZON THERAPEUTICS | 0,030 | +1,69 % | NEURIZON THERAPEUTICS LIMITED: Notification of cessation of securities - NUZ | ||
| CIPHER PHARMACEUTICALS | 9,950 | -1,49 % | Cipher Pharmaceuticals Announces Results of Annual General Meeting of Shareholders | ||
| ACURA PHARMACEUTICALS | - | - | ACURA PHARMACEUTICALS, INC - 8-K, Current Report | ||
| VASO | - | - | Vaso Corporation Announces Financial Results for First Quarter of 2026 | PLAINVIEW, N.Y., May 15, 2026 (GLOBE NEWSWIRE) -- Vaso Corporation ("Vaso") (OTCQX: VASO), a leading MedTech company with a diversified business portfolio in network and IT services, professional... ► Artikel lesen |
EXTRAWELL PHARMACEUTICAL HOLDINGS LTD gehört der Branche Pharma an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu EXTRAWELL PHARMACEUTICAL HOLDINGS LTD finden Sie auf Wallstreet Online.